A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

Jr R. Blumenschein, F. Kabbinavar, H. Menon, T. S K Mok, J. Stephenson, J. T. Beck, K. Lakshmaiah, K. Reckamp, Y. J. Hei, K. Kracht, Y. N. Sun, R. Sikorski, L. Schwartzberg, A. K. Au, C. K. Cheng, T. S K Mok, Y. Tung, D. Behera, R. Chacko, K. LakshmaiahH. Menon, S. Nirni, A. Pathak, R. Thirumulai, F. Arena, J. T. Beck, N. Belman, G. R. Blumenschein, R. Boccia, D. Chan, B. Clowney, S. Davidson, S. Del Prete, A. Dudek, J. Fain, C. Hagenstad, D. Henry, T. Hoang, C. Holladay, E. Hu, F. Kabbinavar, P. Kaywin, W. MacLaughlin, R. March, T. Marsland, L. Meza, F. Mott, R. Page, E. Paschold, G. Patel, R. Patel, D. Prow, K. Reckamp, P. Rosen, K. Sabbath, B. Samuels, L. Schwartzberg, M. Shah, M. Shtivelband, J. Singh, J. Stephenson, D. Subramaniam, P. Swanson, M. Thomas, R. Webb

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences